이뮨온시아, IMC-002로 그린 흑자…CD47 한파 속 희박한 가능성

Immunonsia's 2028 profitability target hinges on securing new IMC-002 licensing deals, yet the CD47 antibody market has significantly cooled following repeated failures by major pharmaceutical companies, creating serious questions about achieving the company's ambitious financial goals.